[go: up one dir, main page]

MA38144A1 - Compositions et procédés pour le traitement de protéinopathies - Google Patents

Compositions et procédés pour le traitement de protéinopathies

Info

Publication number
MA38144A1
MA38144A1 MA38144A MA38144A MA38144A1 MA 38144 A1 MA38144 A1 MA 38144A1 MA 38144 A MA38144 A MA 38144A MA 38144 A MA38144 A MA 38144A MA 38144 A1 MA38144 A1 MA 38144A1
Authority
MA
Morocco
Prior art keywords
methods
mammal
proteinopathies
compositions
treatment
Prior art date
Application number
MA38144A
Other languages
English (en)
Inventor
Sergio Pablo Sardi
Lamya Shihabuddin
Seng Cheng
Original Assignee
Genzyme Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=49578599&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA38144(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Genzyme Corp filed Critical Genzyme Corp
Publication of MA38144A1 publication Critical patent/MA38144A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01045—Glucosylceramidase (3.2.1.45), i.e. beta-glucocerebrosidase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Psychiatry (AREA)
  • Mycology (AREA)
  • Dermatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La présente invention concerne des procédés pour améliorer la fonction neuronale chez un mammifère atteint d'une protéinopathie comprenant l'administration d'une quantité thérapeutiquement efficace d'un agent qui augmente l'activité glucocérébrosidase chez le mammifère. La présente invention concerne en outre des procédés pour réduire les lipides toxiques, de manière à réduire la ?-synucléine, et/ou inhiber l'accumulation d'agrégats de protéines chez un mammifère atteint d'une protéinopathie comprenant l'administration d'une quantité thérapeutiquement efficace d'un agent qui augmente l'activité glucocérébrosidase.
MA38144A 2012-11-05 2013-11-04 Compositions et procédés pour le traitement de protéinopathies MA38144A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261722434P 2012-11-05 2012-11-05
PCT/US2013/068242 WO2014071282A1 (fr) 2012-11-05 2013-11-04 Compositions et procédés pour le traitement de protéinopathies

Publications (1)

Publication Number Publication Date
MA38144A1 true MA38144A1 (fr) 2018-08-31

Family

ID=49578599

Family Applications (1)

Application Number Title Priority Date Filing Date
MA38144A MA38144A1 (fr) 2012-11-05 2013-11-04 Compositions et procédés pour le traitement de protéinopathies

Country Status (22)

Country Link
US (1) US20150284472A1 (fr)
EP (1) EP2914281A1 (fr)
JP (1) JP2016503405A (fr)
KR (1) KR20150079751A (fr)
CN (1) CN104902923A (fr)
AR (1) AR093355A1 (fr)
AU (1) AU2013337354A1 (fr)
BR (1) BR112015009746A2 (fr)
CA (1) CA2889990A1 (fr)
CL (1) CL2015001157A1 (fr)
CR (1) CR20150216A (fr)
EA (1) EA201590880A1 (fr)
HK (1) HK1214521A1 (fr)
IL (1) IL238416A0 (fr)
MA (1) MA38144A1 (fr)
MX (1) MX2015005722A (fr)
PH (1) PH12015500879A1 (fr)
SG (1) SG11201502989XA (fr)
TN (1) TN2015000171A1 (fr)
TW (1) TW201427695A (fr)
WO (1) WO2014071282A1 (fr)
ZA (1) ZA201502618B (fr)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3578195B1 (fr) 2008-06-26 2023-08-09 Zevra Denmark A/S Utilisation du hsp70 en tant que régulateur de l'activité enzymatique
BR112013013143A2 (pt) 2010-11-30 2016-08-23 Orphazyme Aps composto, e, método de tratamento de uma doença de armazenagem lisossômica
HUE054957T2 (hu) 2014-09-15 2021-10-28 Orphazyme As Arimoklomol készítése
WO2016179497A1 (fr) * 2015-05-07 2016-11-10 Shire Human Genetic Therapies, Inc. Thérapie génique par glucocérébrosidase pour la maladie de parkinson
WO2017015491A1 (fr) * 2015-07-21 2017-01-26 Thomas Jefferson University Thérapies géniques pour les troubles neurodégénératifs ciblant les voies de biosynthèse des gangliosides
US10898476B2 (en) 2016-04-13 2021-01-26 Orphazyme A/S Heat shock proteins and cholesterol homeostasis
CA3021900A1 (fr) 2016-04-29 2017-11-02 Orphazyme A/S Arimoclomol pour le traitement de troubles associes a la glucocerebrosidase
EP3264092A1 (fr) * 2016-07-01 2018-01-03 Centogene AG Utilisation de gb1 en tant que cible thérapeutique
MX2019001421A (es) * 2016-08-03 2019-09-04 Univ South Florida Composiciones de reelina para el tratamiento de trastornos neurologicos.
CN112553210B (zh) 2017-10-03 2024-09-24 普利维尔治疗公司 用于溶酶体障碍的基因疗法
US11807849B2 (en) 2017-10-03 2023-11-07 Prevail Therapeutics, Inc. Gene therapies for lysosomal disorders
JP7254815B2 (ja) 2017-10-03 2023-04-10 プリベイル セラピューティクス，インコーポレーテッド ライソゾーム病の遺伝子治療
WO2019084068A1 (fr) * 2017-10-23 2019-05-02 Prevail Therapeutics, Inc. Thérapies géniques pour maladie neurodégénérative
AU2018354318B2 (en) * 2017-10-26 2024-07-04 Takeda Pharmaceutical Company Limited Formulations comprising glucocerebrosidase and isofagomine
WO2019175883A1 (fr) * 2018-03-14 2019-09-19 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd Détection de phospho-sérine 129 alpha-synucléine dans des cellules sanguines en tant que biomarqueur pour synucléinopathies
CA3136117A1 (fr) * 2019-04-10 2020-10-15 Prevail Therapeutics, Inc. Therapies geniques pour troubles lysosomaux
MX2021011958A (es) 2019-04-10 2021-12-15 Prevail Therapeutics Inc Terapias genicas para trastornos lisosomales.
WO2020257736A1 (fr) 2019-06-21 2020-12-24 The Broad Institute, Inc. Agents pour inverser des protéinopathies toxiques
JP2023536080A (ja) 2020-08-06 2023-08-23 ファンダシオン パラ ラ インベスティガシオン メディカ アプリカダ 遺伝子治療によるアルツハイマー病などのタウオパチーの治療に使用するためのウイルス粒子
EP4247792A1 (fr) 2020-11-19 2023-09-27 Zevra Denmark A/S Procédés de préparation de citrate d'arimoclomol et intermédiaires associés
CN112569354B (zh) * 2020-12-29 2022-06-10 四川大学华西医院 tau蛋白及其基因作为药物靶点在制备治疗糖尿病药物中的应用
JP2024546887A (ja) * 2021-12-17 2024-12-26 ジェネンテック， インコーポレイテッド オリゴヌクレオチドｇｂａアゴニスト
WO2023111335A1 (fr) * 2021-12-17 2023-06-22 F. Hoffmann-La Roche Ag Oligonucléotides capables d'augmenter l'expression de la glucocérébrosidase

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US5892019A (en) 1987-07-15 1999-04-06 The United States Of America, As Represented By The Department Of Health And Human Services Production of a single-gene-encoded immunoglobulin
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US6172197B1 (en) 1991-07-10 2001-01-09 Medical Research Council Methods for producing members of specific binding pairs
DK0814159T3 (da) 1990-08-29 2005-10-24 Genpharm Int Transgene, ikke-humane dyr, der er i stand til at danne heterologe antistoffer
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
EP0564531B1 (fr) 1990-12-03 1998-03-25 Genentech, Inc. Methode d'enrichissement pour des variantes de l'hormone de croissance avec des proprietes de liaison modifiees
ATE463573T1 (de) 1991-12-02 2010-04-15 Medimmune Ltd Herstellung von autoantikörpern auf phagenoberflächen ausgehend von antikörpersegmentbibliotheken
ES2249761T3 (es) 1993-06-24 2006-04-01 Advec Inc. Vectores de adenovirus para terapia genica.
CZ291372B6 (cs) 1993-10-25 2003-02-12 Canji, Inc. Rekombinantní adenovirový vektor a jeho použití
US7252989B1 (en) 1994-04-04 2007-08-07 Board Of Regents, The University Of Texas System Adenovirus supervector system
EP0859841B1 (fr) 1995-08-18 2002-06-19 MorphoSys AG Banques de proteines/(poly)peptides
US6696248B1 (en) 1995-08-18 2004-02-24 Morphosys Ag Protein/(poly)peptide libraries
US6924123B2 (en) 1996-10-29 2005-08-02 Oxford Biomedica (Uk) Limited Lentiviral LTR-deleted vector
US6989264B2 (en) 1997-09-05 2006-01-24 Targeted Genetics Corporation Methods for generating high titer helper-free preparations of released recombinant AAV vectors
US6566118B1 (en) 1997-09-05 2003-05-20 Targeted Genetics Corporation Methods for generating high titer helper-free preparations of released recombinant AAV vectors
WO2001002588A2 (fr) 1999-07-02 2001-01-11 Morphosys Ag Production de partenaires de liaison specifiques se liant a des (poly)peptides codes par des fragments d'adn genomiques ou est
PT1204739E (pt) 1999-08-09 2008-11-17 Targeted Genetics Corp Aumento da expressão de uma sequência nucleotídica heteróloga de cadeia simples a partir de vectores virais recombinantes por concepção da sequência de maneira que esta forme pares de bases intracadeia
AU6972301A (en) 2000-06-01 2001-12-11 Univ North Carolina Duplexed parvovirus vectors
US20020095135A1 (en) 2000-06-19 2002-07-18 David Meeker Combination enzyme replacement, gene therapy and small molecule therapy for lysosomal storage diseases
US7446098B2 (en) * 2003-02-18 2008-11-04 Mount Sinai School Of Medicine Of New York University Combination therapy for treating protein deficiencies
US7765583B2 (en) 2005-02-28 2010-07-27 France Telecom System and method for managing virtual user domains
JP5303458B2 (ja) * 2006-06-23 2013-10-02 アミークス セラピューティックス インコーポレイテッド β−グルコセレブロシダーゼの活性増強による神経学的疾患の治療方法
US8454954B2 (en) * 2007-05-16 2013-06-04 The Brigham And Women's Hospital, Inc. Treatment of synucleinopathies
AU2012272815B2 (en) 2011-06-22 2017-09-07 The General Hospital Corporation Treatment of proteinopathies
AU2013240187A1 (en) 2012-03-28 2014-10-30 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Salicylic acid derivatives useful as glucocerebrosidase activators

Also Published As

Publication number Publication date
TW201427695A (zh) 2014-07-16
KR20150079751A (ko) 2015-07-08
AU2013337354A1 (en) 2015-05-21
EA201590880A1 (ru) 2015-09-30
CA2889990A1 (fr) 2014-05-08
SG11201502989XA (en) 2015-05-28
JP2016503405A (ja) 2016-02-04
ZA201502618B (en) 2016-01-27
MX2015005722A (es) 2016-01-12
PH12015500879A1 (en) 2015-06-29
IL238416A0 (en) 2015-06-30
HK1214521A1 (zh) 2016-07-29
CR20150216A (es) 2015-05-29
BR112015009746A2 (pt) 2017-08-15
WO2014071282A1 (fr) 2014-05-08
CN104902923A (zh) 2015-09-09
CL2015001157A1 (es) 2015-10-16
EP2914281A1 (fr) 2015-09-09
AR093355A1 (es) 2015-06-03
TN2015000171A1 (fr) 2016-10-03
US20150284472A1 (en) 2015-10-08

Similar Documents

Publication Publication Date Title
MA38144A1 (fr) Compositions et procédés pour le traitement de protéinopathies
SG10201804552WA (en) Nanoparticle compositions, formulations thereof, and uses therefor
MA32397B1 (fr) Agonistes mixtes basés sur gip destinés au traitement de troubles métaboliques et de l'obésité
MA41759A (fr) Inclusion de l'exon 2, induite par antisens, dans une alpha-glucosidase acide
MA32132B1 (fr) Utilisation de ranolazine pour traiter la douleur
MA39094B1 (fr) Polythérapie comprenant un inhibiteur de mdm2 et un ou plusieurs principes pharmaceutiquement actifs supplémentaires pour le traitement de cancers
MA43283B1 (fr) Composition pour le traitement du cancer
MA35873B1 (fr) Variants polypeptidiques du récepteur de l'activine, seuls ou en combinaison avec une chimiothérapie, et leurs utilisations
BR112014028017A2 (pt) composto, composição farmacêutica, método para tratar um distúrbio, método para reduzir a quantidade il-17 em um indivíduo e método para inibir a atividade de ror
MA33295B1 (fr) Nouvelle formulation de diclofénac
MA34726B1 (fr) Prévention des effets secondaires provoqués par des domaines de liaison spécifiques de cd3
MA38478A1 (fr) Anticorps anti-pac1 humains
MA37946A1 (fr) Traitement de la polyarthrite rhumatoïde
NZ702087A (en) Pharmaceutical compositions and treatment of mastitis
MA40283A (fr) Aptamères spécifiques du récepteur tlr-4 et leurs utilisations
WO2020072126A8 (fr) Modulation de ptpn2 pour accroître les réponses immunitaires et perturber l'expression génique dans des lignées de cellules souches hématopoïétiques
MX2012012355A (es) Composiciones organicas para tratar enfermedades relacionadas con beta-enac.
MA20150436A1 (fr) Préparation pharmaceutique
WO2011087548A3 (fr) Compositions thérapeutiques et méthodes d'administration ciblée de principes actifs
MX2018005352A (es) Metodos y composiciones para el tratamiento de amiloidosis.
MA34815B1 (fr) Compositions comprenant un inhibiteur de pi3k et un inhibiteur de mek et leur utilisation pour le traitement du cancer
FR2972330B1 (fr) Composition nutraceutique pour limiter l'absorption de lipides alimentaires et pour induire une perte de poids comprenant comme agent actif au moins un extrait de carotte.
MA38369A1 (fr) Peptides et compositions pour le traitement d'une lesion de l'articulation
EP3309555A3 (fr) Procédés de prévention ou de traitement de troubles par augmentation de la biodisponibilité du fer et formulation pharmaceutique apparentée
WO2019017677A3 (fr) Composition comprenant du citral utilisé comme principe actif pour présenter un effet de raffermissement musculaire, de renforcement musculaire, de différenciation musculaire, de régénération musculaire ou de suppression de sarcopénie